ITRM — Iterum Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $38.04m
- $59.45m
Annual cashflow statement for Iterum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52 | -91.6 | -44.4 | -38.4 | -24.8 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 21.9 | 74.1 | 21.9 | -5.47 | 10.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -24.6 | -0.44 | 2.31 | 2.76 | -12.7 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -54.5 | -15.8 | -18.5 | -39.3 | -26.8 |
| Capital Expenditures | -0.011 | -0.061 | -0.062 | -0.013 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -54.5 | 14 | 23.3 | 18.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.011 | -54.6 | 14 | 23.3 | 18.2 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 64.5 | 83.1 | -1.82 | 1.03 | 26.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.93 | 12.7 | -6.38 | -15 | 18.1 |